BRUSSELS, Nov 4 (Reuters) - EU antitrust regulators will

decide by Dec. 6 whether to clear Novo Holdings' acquisition of

contract drug manufacturer Catalent ( CTLT ), according to a

filing on the European Commission website on Monday.

The controlling shareholder of Novo Nordisk put

in a request for EU approval for the deal on Oct. 31, the filing

showed.

The EU antitrust can either clear the deal with or without

remedies or it can open a full-scale four-month long

investigation if it has serious concerns.